Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
- Mechanism
- Curator reviewed
Bitolterol is an adrenergic beta-2 agonist. Asthma results from a narrowing of the bronchial tubes. This narrowing is caused by muscle spasm and inflammation within the bronchial tubes. Agonism of the beta-2 adrenergic receptors by bitolterol leads to a relaxation of the smooth muscles surrounding these airway tubes which then increases the diameter and ease of air flow through the tubes.
- Primary indication
- Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation.Curator reviewed
- Formula / weight
- C28H31NO5 · 461.5494 g/mol (avg)
Resolves to
FZGVEKPRDOIXJY-UHFFFAOYSA-NSMILESCC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)CWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Bitolterol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account